Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncology

• Publication date

  2017-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000479818PMID 28869928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

  2017cited by this paper
• The mitosis‐specific marker phosphohistone‐H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome‐based study

  2017cited by this paper
• The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.

  2016cited by this paper
• Uterine fibroids

  2016cited by this paper
• Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential

  2016cited by this paper
• Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors

  2016cited by this paper
• Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.

  2014cited by this paper
• Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors

  2012cited by this paper
• [Uterine Sarcomas - a review].

  2012cited by this paper
• Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.

  2011cited by this paper
• Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.

  2011cited by this paper
• Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors

  2011cited by this paper
• Uterine Smooth Muscle Tumors Other Than the Ordinary Leiomyomas and Leiomyosarcomas: A Review of Selected Variants With Emphasis on Recent Advances and Unusual Morphology That May Cause Concern for Malignancy

  2010cited by this paper
• Atypical Leiomyomas of the Uterus With Long-term Follow-up After Myomectomy With Immunohistochemical Analysis for p16INK4A, p53, Ki-67, Estrogen Receptors, and Progesterone Receptors

  2009cited by this paper
• Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.

  2009cited by this paper
• Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP):: A Clinicopathologic Analysis of 16 Cases

  2009cited by this paper
• Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.

  2009cited by this paper
• The Use of p16 in Enhancing the Histologic Classification of Uterine Smooth Muscle Tumors

  2008cited by this paper
• Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential

  2007cited by this paper
• Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.

  2005cited by this paper
• Endometrioid Carcinoma of the Uterine Corpus: A Review of Its Pathology With Emphasis on Recent Advances and Problematic Aspects

  2002cited by this paper
• Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.

  1999cited by this paper
• p53 alterations in uterine leiomyosarcomas versus leiomyomas.

  1994cited by this paper
• Problematic Uterine Smooth Muscle Neoplasms: A Clinicopathologic Study of 213 Cases

  1994cited by this paper
• Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

  1993cited by this paper
• The frequency of uterine leiomyomas.

  1990cited by this paper
• Uterine leiomyomata: etiology, symptomatology, and management.

  1981cited by this paper

• The estrogen-progestogen-oxidative stress network in uterine fibroids: mechanistic insights and therapeutic opportunities

  2026cites this paper
• Gene variants polymorphisms and uterine leiomyoma: an updated review

  2024cites this paper
• Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas

  2024cites this paper
• Uterine smooth muscle tumor of uncertain malignant potential: A review of current knowledge.

  2022cites this paper
• Neck subcutaneous nodule as first metastasis from broad ligament leiomyosarcoma: a case report and review of literature

  2020cites this paper
• Oncologic and Reproductive Outcomes of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: A Single Center Retrospective Study of 67 Cases

  2020cites this paper
• Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes

  2019cites this paper
• The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium

  2019cites this paper
• Expanded Somatic Mutation Spectrum of MED12 Gene in Uterine Leiomyomas of Saudi Arabian Women

  2018cites this paper